Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III–IVB head and neck squamous cell carcinoma (HNSCC)

BACKGROUND: There is a clinical need to improve the efficacy of standard cetuximab + concurrent intensity-modulated radiation therapy (IMRT) for patients with locally and/or regionally advanced HNSCC. Taxanes have radiosensitizing activity against HNSCC, and nab-paclitaxel may offer therapeutic adva...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Fury, M. G., Sherman, E. J., Rao, S. S., Wolden, S., Smith-Marrone, S., Mueller, B., Ng, K. K., Dutta, P. R., Gelblum, D. Y., Lee, J. L., Shen, R., Kurz, S., Katabi, N., Haque, S., Lee, N. Y., Pfister, D. G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2014
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433511/
https://ncbi.nlm.nih.gov/pubmed/24496920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt579
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller